premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly Our Top Pick of SR is as much a seasonal play as it is about fundamental recovery. This natural gas company provides service to 1.8 million homes in Alabama, Missouri and Mississippi, is the 5th largest publicly traded natural gas company, and is viewed as providing essential services heading into the winter. Recent earnings were up 3% over the year and consensus calls for a 9% increase next year. We would trade this with a stop-loss at $50. Yield 4.54% (Analysts’ price target is $72.89)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly One of the sectors that has benefitted from the pandemic is that of grocers. VLGEA is a under-the-radar grocer that provides a solid divided, backed up by a safe payout ratio. The company just reported a 20% increase in revenues over the year and EPS was up 34%. Its 15.8 PE is half of the sector average and it trades at 1.1 times book. They recently acquired the Fairway Market assets, which included four stores in the NYC area and a distribution centre. We would trade this with a $20 stop-loss and look for upside towards $30 -- 22% potential. Yield 4.11% (Analysts’ price target is $26.90)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly This medical device company has has been front and centre during the pandemic -- providing six COVID-19 test kits -- including one now that provides results in 15 minutes. The company's other products help patients with chronic cardiovascular, pulminary, and diabetic issues. The company is launching a new non-finger poking glucose monitoring device -- a game changer. A recent pullback in the share price gives an opportunity to enter with reasonable upside. We would trade this with a $97 stop-loss looking to achieve $128 -- 17% upside. Yield 1.34% (Analysts’ price target is $115.12)
COMMENT
Announcement of government funding to Ford's electric vehicle division. Wind at the back of the Ontario economy. Seeing pickup in auto demand. Auto industry is a real backbone and will have a really nice recovery over the next few years.
COMMENT
Is Washington stimulus or lack thereof a big market driver? Stimulus is a necessary bridge. Recovery is uneven. If certain sectors don't get stimulus, there will be bankruptcies and a domino effect. A stimulus package will get through and will be very bullish.
RISKY

Execution and funding risk. There are safer names like ENB and PPL. If they pull off this execution on time and on budget, there's meaningful upside. Balance sheet pretty levered. Not as cheap as peers. It can work, but it's a riskier play.

BUY
Likes it a lot. Good EPS growth. Not cheap anymore. If Biden wins, it will favour the renewables. Liked it more a couple of weeks ago in the $18s. Will grow in next 5 years.
BUY
Incredibly high dividend of 8.4%, which is sometimes a signal of trouble. Payout ratio pretty stable around 71%. Trading at a compelling 13.3x 2021 PE. Improved balance sheet. Volumes back to pre-Covid levels. Decent 7% EPS growth. Risks on Lines 3 and 5. On balance, nice risk/reward at these levels.
COMMENT
How safe are pipelines? Pretty safe. No commodity risk. Needed infrastructure to harness any growth in the oil space. Risk if oil completely falls apart or producers go away. That's unlikely. Oil will still have its place.
DON'T BUY

Likes it. OK growth rate. Expensive. AQN and FTS are trading at better levels with nice growth rates and dividend growth. Pretty safe area, but a mistake to buy at the top of the range.

BUY

AQN vs. H Likes Hydro One, with an OK growth rate, but it's expensive. AQN and FTS are trading at better levels than Hydro One with nice growth rates and dividend growth. Pretty safe area, but a mistake to buy at the top of the range.

BUY

FTS vs. H Likes Hydro One, with an OK growth rate, but it's expensive. AQN and FTS are trading at better levels than Hydro One with nice growth rates and dividend growth. Pretty safe area, but a mistake to buy at the top of the range.

DON'T BUY
135% payout ratio, not sustainable. But if business returns, as he thinks it will, payout ratio will go down to 62%. Real problem is balance sheet. Need to focus on asset sales. Has upside, but pretty risky. Better yield stories elsewhere.
BUY
Telus Health going well. Small impact from Covid. High dividend with 6% growth. Great name. Not cheap. Part of the solution in the thirst for data. Best of the bunch.
HOLD
Top of the range. Very expensive. Rails are on fire. Volumes will probably exceed this quarter. Nice, visible growth rates. Hold if you own, but don't chase at these levels.